Results: Patients with PAD had elevated serum high-sensitivity C-reactive protein (3.7 vs 0.6 mg/L; P ¼ .004) and interleukin (IL) 6 (5.1 vs 1.1 pg/mL; P ¼ .01) and trended toward higher levels of monocyte chemoattractant protein 1 and lower adiponectin compared with healthy individuals. Circulating monocytes and polymorphonuclear cells (PMNs) from PAD patients had reduced phagocytic activity for E. coli (monocytes, >30% [P < .001]; PMNs, >25% [P < .01]). Flow cytometry demonstrated a higher proportion of the proinflammatory intermediate monocyte subset (CD14  ++ 16 + , 1.8-fold; P ¼ .04) in PAD subjects. MDMs from PAD patients retain their intrinsic inflammatory program, producing more IL-6 (>4-fold; P ¼ .03) and IL-1b (>10-fold; P ¼ .04) and demonstrating increased expression of M1 genes (tumor necrosis factor a, monocyte chemoattractant protein 1, CXCL10) and decreased expression of M2 genes (CCL17, MRC1) vs healthy individuals (Table) .
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Conclusions: Clinically stable PAD patients have elevated serum inflammatory markers compared with healthy individuals. Circulating monocytes and PMNs in patients with PAD have reduced phagocytic activity and a greater proportion of the proinflammatory intermediate monocyte subset. MDMs from PAD patients preserve their elevated inflammatory state in culture. These data demonstrate a heightened inflammatory and impaired resolution phenotype in PAD that has potential implications for disease progression and response to interventions.
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Outcomes of Hemodialysis Vascular Access in Patients Initiating Dialysis With a Tunneled Catheter
Timothy Copeland, Peter Lawrence, Karen Woo. UCLA, Los Angeles, Calif
Objective: The objective of this study was to determine factors that influence time to removal of tunneled hemodialysis catheter (THC), probability of repeated vascular access creation, and time to repeated vascular access.
Methods: The Optum (Eden Prairie, Minn) Clinformatics database, which contains claims from a large managed care organization, from 2011 to 2016 was queried for patients who initiated hemodialysis with a THC. Time from initial arteriovenous fistula (AVF) or arteriovenous graft (AVG) to THC removal and time to repeated AVF or AVG were analyzed using Cox proportional hazards. Multivariate models included age, sex, race, diabetes, cardiac arrhythmia, congestive heart failure, peripheral vascular disease, and obesity as covariates.
Results: There were 8355 vascular accesses that met the inclusion criteria 6648 (77%) AVFs and 1940 (23%) AVGs. Median follow-up was 424 days (range, 1-2097 days). Patients undergoing AVF were younger and more likely to be male and white (Table) . At 90 days, 20.3% (95% confidence interval [CI] , 19.3%-20.3%) of AVFs vs 56% (95% CI, 53.7%-58.4%) of AVGs had the THC removed. At 180 days, 56.7% (95% CI, 55.4%-58.1%) of AVFs vs 68.4% (95% CI, 66.1%-70.6%) of AVGs had the THC removed. By day 315, 74% of patients with both AVFs and AVGs had the THC removed. Multivariate analysis demonstrated a significant interaction between vascular access type and age $70 years (P < .001). In the age group <70 years, patients who underwent AVG had a THC removal rate 46% higher than that of patients who underwent AVF. In the age group $70 years, patients who underwent AVG had a THC removal rate 88% higher than that of patients who underwent AVF. There were 1982 (23.7%) patients who underwent a second vascular access. Multivariate analysis demonstrated that AVG vs AVF (odds ratio, 0.70; 95% CI, 0.61-0.81) and age $70 years vs <70 years (odds ratio, 0.87; 95% CI, 0.78-0.98) were associated with a lower odds of second access. In patients who underwent a second access, multivariate analysis demonstrated that initial AVG was associated with longer time to second access (hazard ratio, 0.60; 95% CI, 0.54-0.68).
Conclusions: Creation of AVG vs AVF significantly decreased the time to THC removal in dialysis-dependent patients, with a larger difference in patients aged $70 years vs <70 years. Initial AVG was associated with lower odds of second access and longer time to second access in those who underwent second access. These results contradict the dictum of Expression fold change was calculated as 2 ˇ ( eDDCT) and represents the fold change in the average expression of the target gene within the PAD cohort (n ¼ 10) vs the average expression of the target gene within the cohort of healthy individuals (n ¼ 10), normalized to the housekeeping gene (HPRT). MDMs were stimulated with lipopolysaccharide to mimic the occurrence of an acute inflammatory event or vehicle for 24 hours before assessment of gene expression. a P < .05 by unpaired Student t-test. 
